Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging

Clinical Cancer Research

Volumn 18, Issue 23, 2012, Pages 6469-6477

  Nielsen, Thomas ^a,b   Bentzen, Lise ^a   Pedersen, Michael ^a   Tramm, Trine ^a   Rijken, Paul F J W ^c   Bussink, Johan ^c   Horsman, Michael R ^a   Søtergaard, Leif ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; HOE 33342; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CELL HETEROGENEITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HISTOGRAM; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSELS; DISEASE MODELS, ANIMAL; FEMALE; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES;

EID: 84870332928     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2014     Document Type: Article

References (50)

1. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009;18: 189-97.
2. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34. (Pubitemid 27209705)
3. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998;42:899-903. (Pubitemid 28559439)
4. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59: 1626-34. (Pubitemid 29160136)
5. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204. (Pubitemid 32158366)
6. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6. (Pubitemid 34273190)
7. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81:1318-27.
8. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-95. (Pubitemid 29168237)
9. Siemann DW. Vascular targeting agents. Horizons Cancer Ther 2002;3:4-15.
10. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35. (Pubitemid 40791485)
11. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22. (Pubitemid 32785286)
12. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16. (Pubitemid 34651387)
13. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42. (Pubitemid 46621830)
14. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38. (Pubitemid 46621821)
15. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61: 6811-5. (Pubitemid 32896505)
16. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002; 15:89-98. (Pubitemid 34213398)
17. Bentzen L, Vestergaard-Poulsen P, Nielsen T, Overgaard J, Bjørnerud A, Briley-Saebø K, et al. Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. Int J Radiat Oncol Biol Phys 2005;61:1208-15. (Pubitemid 40340917)
18. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med 1994;32:749-63. (Pubitemid 24371176)
19. Kennan RP, Zhong J, Gore JC. Intravascular susceptibility contrast mechanisms in tissues. Magn Reson Med 1994;31:9-21. (Pubitemid 24016936)
20. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555-66.
21. Østergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. part I: mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-25. (Pubitemid 26376710)
22. Østergaard L, Sørensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. part II: experimental comparison and preliminary results. Magn Reson Med 1996;36: 726-36. (Pubitemid 26376711)
23. Kiselev VG. On the theoretical basis of perfusion measurements by dynamic susceptibility contrast MRI. Magn Reson Med 2001;46: 1113-22. (Pubitemid 33104300)
24. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-9. (Pubitemid 28543828)
25. Troprès I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, et al. Vessel size imaging. Magn Reson Med 2001;45:397-408. (Pubitemid 32173265)
26. Troprès I, Lamalle L, Farion R, Segebarth C, Rémy C. Vessel size imaging using low intravascular contrast agent concentrations. MAGMA 2004;17:313-6. (Pubitemid 40362315)
27. Kiselev VG, Strecker R, Ziyeh S, Speck O, Hennig J. Vessel size imaging in humans. Magn Reson Med 2005;53:553-63. (Pubitemid 40332275)
28. Quarles CC, Schmainda KM. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magn Reson Med 2007;57:680-7. (Pubitemid 46731793)
29. Lemasson B, Valable S, Farion R, Krainik A, Remy C, Barbier EL. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med. 2012 Mar 16. [Epub ahead of print].
30. Robinson SP, Rijken PF, Howe FA, McSheehy PM, van der Sanden BP, Heerschap A, et al. Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. J Magn Reson Imaging 2003;17: 445-54. (Pubitemid 36396947)
31. Kostourou V, Robinson SP, Whitley GS, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibilitymagnetic resonance imaging. Cancer Res 2003;63:4960-6. (Pubitemid 37022632)
32. Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Waterton JC. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126. Int J Radiat Oncol Biol Phys 2007;69:872-9. (Pubitemid 47418423)
33. Robinson SP, Ludwig C, Paulsson J, Ostman A. The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI. Int J Cancer 2008;122:1548-56. (Pubitemid 351294963)
34. Howe FA, McPhail LD, Griffiths JR, McIntyre DJ, Robinson SP. Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model. Int J Radiat Oncol Biol Phys 2008;71:1470-6.
35. Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Ostergaard L, Horsman MR. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys 2008;70:859-66.
36. Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001;17: 508-19. (Pubitemid 33048907)
37. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047-55. (Pubitemid 37324123)
38. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980;6:1507-17. (Pubitemid 11253966)
39. Chen G, Jespersen S, Pedersen M, Pang Q, Horsman MR, Jørgensen HS. Evaluation of anti-vascular therapy with texture analysis. Anticancer Res 2005;25:3399-405. (Pubitemid 41105217)
40. Rijken PF, Bernsen HJ, van der Kogel AJ. Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. Microvasc Res 1995;50: 141-53.
41. Hendriksen EM, Span PN, Schuuring J, Peters JP, Sweep FC, van der Kogel AJ, et al. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 2009;77:96-103.
42. Abramovitch R, Dafni H, Smouha E, Benjamin LE, Neeman M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res 1999;59:5012-6. (Pubitemid 29472908)
43. Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 2002;87:673-80.
44. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88: 1592-7. (Pubitemid 36713788)
45. Walker-Samuel S, Boult JK, McPhail LD, Box G, Eccles SA, Robinson SP. Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts. Int J Cancer 2012;130:1284-93.
46. Hilmas DE, Gillette EL. Morphometric analyses of the microvasculature of tumors during growth and after x-irradiation. Cancer 1974;33: 103-10.
47. Hilmas DE, Gillette EL. Microvasculature of C3H/Bi mouse mammary tumors after x-irradiation. Radiat Res 1975;61:128-43.
48. Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 2005;7:466-74. (Pubitemid 40791866)
49. McPhail LD, Griffiths JR, Robinson SP. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2007;69:1238-45. (Pubitemid 47625879)
50. Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 2011;17:5695-704.